الرئيسية » أخبار

أخبار

The future of genome editing in Europe – Bringing together the views of government, industry, patient communities, and civil society’ representatives

  Genome editing is a breakthrough healthcare technology which has the potential to notably change treatment options, largely influence current healthcare models, and impact patients in clinical trials worldwide. The science is advancing rapidly, promising considerable increases in the efficacy and precision of genome editing products with potentially curative treatments ...

أكمل القراءة »

TIF joined the Celgene’s Blood Transfusion Round Table Discussion in Brussels

On September 26, a Blood Transfusion Multi-Stakeholder Round Table Discussion was organised in Brussels by Celgene Corporation, featuring numerous scientists, haematologists, and patient organisations’ representatives. Dr. Androulla Eleftheriou, TIF Executive Director, and Mrs. Lily Cannon, TIF Operations Manager, represented the Federation in this meeting. The discussion drew attention to issues ...

أكمل القراءة »

Hypertension Medication Valsartan May Help Prevent Vaso-Occlusive Episodes in Sickle Cell Disease

A medication used to treat high blood pressure, called Valsartan, may help decrease the stickiness of red blood cells and reduce the risk of vaso-occlusive crisis in people with sickle cell disease (SCD), a research study suggests. The study, “Valsartan impedes epinephrine-induced ICAM-4 activation on normal, sickle cell trait and sickle cell ...

أكمل القراءة »

Cypriot Stella Kyriakides named EU Health Commissioner

Cypriot psychologist and politician to take over from Vytenis Andriukaitis on November 1 Stella Kyriakides has got the nod as EU Commissioner for Health, making her part of a strong female presence in the new structure of the next European Commission. Kyriakides, one of 13 women commissioners from 27, replaces ...

أكمل القراءة »

TIF releases new video on thalassaemia prevention

  Thalassaemia is a hereditary blood disease that CAN be prevented! But in what ways? ΤΙF’s latest educational video shines a spotlight on the essential aspect of the disease’s prevention, still challenging  in numerous countries across the world. Our goal? To further improve understanding and knowledge of the prevention’s vital ...

أكمل القراءة »

Deferasirox Mylan: A new generic drug for the treatment of iron overload in β-thalassaemia major pending approval by the EMA

  The Committee for Medicinal Products for Human Use (CHMP), the European Medicines Agency’s (EMA) committee responsible for human medicines, has recently adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product ”Deferasirox Mylan”, intended for the treatment of chronic iron overload due to blood transfusions in patients with ...

أكمل القراءة »